{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:02:28Z","timestamp":1790920948686,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,10,1]]},"DOI":"10.1097\/qai.0b013e31814258c0","type":"journal-article","created":{"date-parts":[[2007,7,20]],"date-time":"2007-07-20T04:07:22Z","timestamp":1184904442000},"page":"174-180","source":"Crossref","is-referenced-by-count":23,"title":["Low-Level K65R Mutation in HIV-1 Reverse Transcriptase of Treatment-Experienced Patients Exposed to Abacavir or Didanosine"],"prefix":"10.1097","volume":"46","author":[{"given":"Evguenia S","family":"Svarovskaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A","family":"Margot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katyna","family":"Borroto-Esoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210131","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1128\/JCM.00449-06","article-title":"Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.","volume":"44","author":"Halvas","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R2-7-20210131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa041305","article-title":"Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.","volume":"351","author":"Jourdain","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-7-20210131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00126334-200501010-00007","article-title":"Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.","volume":"38","author":"Lecossier","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-7-20210131","first-page":"5150","article-title":"Low frequency non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant variants contribute to failure of efavirenz-containing regimens in NNRTI-experienced patients with negative standard genotypes for NNRTI mutations [abstract].","volume":"8","author":"Mellors","year":"2003","journal-title":"Antivir Ther"},{"key":"R5-7-20210131","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jcv.2004.05.020","article-title":"Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.","volume":"32","author":"Delaugerre","year":"2005","journal-title":"J Clin Virol"},{"issue":"Suppl 1","key":"R7-7-20210131","first-page":"S41","article-title":"Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection [abstract].","volume":"11","author":"Van Rompay","year":"2006","journal-title":"Antivir Ther"},{"key":"R8-7-20210131","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1086\/315317","article-title":"Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy.","volume":"181","author":"Harrigan","year":"2000","journal-title":"J Infect Dis"},{"key":"R9-7-20210131","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00002030-200001280-00012","article-title":"HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.","volume":"14","author":"Miller","year":"2000","journal-title":"AIDS"},{"key":"R10-7-20210131","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/AAC.41.4.757","article-title":"Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.","volume":"41","author":"Winters","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-7-20210131","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.qai.0000147521.34369.c9","article-title":"Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.","volume":"38","author":"Moyle","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-7-20210131","doi-asserted-by":"crossref","first-page":"25489","DOI":"10.1074\/jbc.M313534200","article-title":"A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions.","volume":"279","author":"Deval","year":"2004","journal-title":"J Biol Chem"},{"key":"R13-7-20210131","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/135965359900400205","article-title":"In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.","volume":"4","author":"Wainberg","year":"1999","journal-title":"Antivir Ther"},{"key":"R14-7-20210131","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/135965350400900303","article-title":"Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.","volume":"9","author":"Masquelier","year":"2004","journal-title":"Antivir Ther"},{"key":"R15-7-20210131","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.","volume":"189","author":"Miller","year":"2004","journal-title":"J Infect Dis"},{"key":"R16-7-20210131","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1128\/JCM.01512-06","article-title":"MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.","volume":"44","author":"Svarovskaia","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R17-7-20210131","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00006","article-title":"Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection.","volume":"139","author":"Squires","year":"2003","journal-title":"Ann Intern Med"},{"key":"R18-7-20210131","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/00002030-200206140-00008","article-title":"Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.","volume":"16","author":"Schooley","year":"2002","journal-title":"AIDS"},{"key":"R19-7-20210131","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00002030-200206140-00004","article-title":"Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.","volume":"16","author":"Margot","year":"2002","journal-title":"AIDS"},{"key":"R20-7-20210131","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/00126334-200411010-00002","article-title":"Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.","volume":"37","author":"McColl","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-7-20210131","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/JCM.43.1.406-413.2005","article-title":"Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.","volume":"43","author":"Palmer","year":"2005","journal-title":"J Clin Microbiol"},{"key":"R22-7-20210131","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.292.2.180","article-title":"Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.","volume":"292","author":"Saag","year":"2004","journal-title":"JAMA"},{"key":"R23-7-20210131","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1086\/379215","article-title":"Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.","volume":"188","author":"Metzner","year":"2003","journal-title":"J Infect Dis"},{"key":"R24-7-20210131","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1128\/JCM.43.11.5696-5704.2005","article-title":"Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.","volume":"43","author":"Nissley","year":"2005","journal-title":"J Clin Microbiol"},{"key":"R25-7-20210131","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.aids.0000216370.69066.7f","article-title":"Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.","volume":"20","author":"Palmer","year":"2006","journal-title":"AIDS"},{"key":"R26-7-20210131","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nmeth713","article-title":"LigAmp for sensitive detection of single-nucleotide differences.","volume":"1","author":"Shi","year":"2004","journal-title":"Nature Methods"},{"issue":"Suppl 1","key":"R27-7-20210131","first-page":"S79","article-title":"Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral-naive HIV-1-infected persons [abstract].","volume":"11","author":"Johnson","year":"2006","journal-title":"Antivir Ther"},{"key":"R28-7-20210131","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1089\/aid.2006.22.912","article-title":"Short communication: a rapid and sensitive real-time PCR assay for the K65R drug resistance mutation in SIV reverse transcriptase.","volume":"22","author":"Johnson","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R29-7-20210131","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jama.288.2.169","article-title":"Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.","volume":"288","author":"Hammer","year":"2002","journal-title":"JAMA"},{"key":"R30-7-20210131","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1086\/430742","article-title":"Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.","volume":"192","author":"Flys","year":"2005","journal-title":"J Infect Dis"},{"key":"R31-7-20210131","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/01.qai.0000221686.67810.20","article-title":"Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.","volume":"42","author":"Flys","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R32-7-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/430745","article-title":"Single-dose nevirapine and drug resistance: the more you look, the more you find.","volume":"192","author":"Hammer","year":"2005","journal-title":"J Infect Dis"},{"key":"R33-7-20210131","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/430741","article-title":"Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.","volume":"192","author":"Johnson","year":"2005","journal-title":"J Infect Dis"},{"key":"R34-7-20210131","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1128\/JVI.80.10.4971-4977.2006","article-title":"The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.","volume":"80","author":"Parikh","year":"2006","journal-title":"J Virol"},{"key":"R35-7-20210131","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/505711","article-title":"Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level.","volume":"194","author":"Parikh","year":"2006","journal-title":"J Infect Dis"},{"key":"R36-7-20210131","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/00002030-200410210-00018","article-title":"Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.","volume":"18","author":"Valer","year":"2004","journal-title":"AIDS"},{"key":"R37-7-20210131","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/135965350601100209","article-title":"The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.","volume":"11","author":"White","year":"2006","journal-title":"Antivir Ther"},{"key":"R38-7-20210131","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jcv.2006.07.001","article-title":"Coexistence of the K65R\/L74V and\/or K65R\/T215Y mutations on the same HIV-1 genome.","volume":"37","author":"Henry","year":"2006","journal-title":"J Clin Virol"},{"key":"R39-7-20210131","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1128\/JVI.77.10.5685-5693.2003","article-title":"A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.","volume":"77","author":"Garcia-Lerma","year":"2003","journal-title":"J Virol"},{"key":"R40-7-20210131","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1086\/510745","article-title":"Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.","volume":"44","author":"Sungkanuparph","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAI.0b013e31814258c0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:48:44Z","timestamp":1786034924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200710010-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31814258c0","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10,1]]}}}